Athersys Stock News

Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human life continues to stretch further ahead.

The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding

Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing po

Athersys (NASDAQ: ATHX ) stock is falling on Friday after the biotechnology company announced a public stock offering. That public offering has Athersys selling 10,937,500 shares of ATHX stock for a

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it wil

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it wil

Upgrades Goldman Sachs upgraded the previous rating for iQIYI Inc (NASDAQ:IQ) from Neutral to Buy. iQIYI earned $0.14 in the fourth quarter, compared to $0.35 in the year-ago quarter. At the moment, t

CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it w

Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares rose 74.7% to $0.4104 in pre-market trading after declining 4% on Wednesday. Surrozen, Inc. (NASDAQ: SRZN) shares rose 67.3% to $0.7291 in pre-mark

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares rose 26.3% to $0.7994 in pre-market trading after the company received FDA 510K premarket clearance for PainShield Plus, its dual-actuator ultrasound

Athersys, Inc. (NASDAQ:ATHX ) Q3 2022 Earnings Conference Call November 15, 2022 11:00 AM ET Company Participants Ellen Gurley – Corporate Communications and Investor Relations Dan Camardo – Chief

CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in

Gainers Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares climbed 212.8% to close at $12.51 on Wednesday after partner Ipsen reported Onivyde met its primary and key secondary endpoint. Merrimac

U.S. stocks traded lower toward the end of trading , with the Nasdaq Composite dropping 200 points on Wednesday. The Dow traded down 1.44% to 32,684.65 while the NASDAQ fell 1.89% to 10,416.00. The S&